HGH Fragment 176-191 — Indexed Studies

Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.

Vanhee C, Moens G, Deconinck E et al.

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Habibullah MM, Mohan S, Syed NK et al.

Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.

Thomas A, Görgens C, Guddat S et al.

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.

Kwon DR, Park GY

Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.

Thevis M, Thomas A, Schänzer W

Detection and in vitro metabolism of AOD9604.

Cox HD, Smeal SJ, Hughes CM et al.

AOD-9604 does not influence the WADA hGH isoform immunoassay.

Orlovius AK, Thomas A, Schänzer W et al.

Gateways to clinical trials.

Bayés M, Rabasseda X, Prous JR

Gateways to clinical trials.

Bayes M, Rabasseda X, Prous JR

Gateways to clinical trials.

Bayés M, Rabasseda X, Prous JR

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

Heffernan M, Summers RJ, Thorburn A et al.

Hyperglycemic action of synthetic C-terminal fragments of human growth hormone.

Ng FM, Bornstein J

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Rahman OF, Lee SJ, Seeds WA

Human sports drug testing by mass spectrometry.

Schänzer W, Thevis M

Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.

Thevis M, Schänzer W

Obesity drugs in clinical development.

Halford JC

AOD-9604 Metabolic.

Wilding J